- •Foreword
- •List of contributors
- •Preface
- •Dedication and Acknowledgments
- •Evolving knowledge in pharmacologic treatments
- •MEDICAL TREATMENT
- •VERTEPORFIN
- •ANTI-VEGF TREATMENT
- •OTHER MEDICAL TREATMENTS
- •“PLAYERS” IN OCULAR TREATMENT
- •THE DRUG
- •ROUTE OF ADMINISTRATION
- •Eye drops
- •Soluble ophthalmic drug inserts
- •Ion drug exchange
- •Intravitreal injections
- •Systemic administration
- •Sustained drug delivery system
- •Intraocular implants
- •Microparticles and nanoparticles
- •Liposomes
- •Encapsulated cell technology (ECT)
- •Iontophoresis
- •REFERENCES
- •SECTION 1: Basic Sciences in Retina
- •Retinal anatomy and pathology
- •INTRODUCTION
- •KEY CONCEPTS AND FUNDAMENTALS
- •NORMAL RETINAL ANATOMY
- •RETINAL PATHOLOGY
- •Congenital abnormalities
- •Dystrophies
- •Degenerations
- •Vascular diseases
- •Toxicities
- •Inflammatory diseases
- •Neoplasms
- •Retinal detachment
- •Trauma
- •Involvement of systemic diseases
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •Retinal biochemistry, physiology, and cell biology
- •INTRODUCTION
- •VITREOUS BIOCHEMISTRY
- •VITREOUS DEGENERATION WITH AGING
- •PHYSIOLOGICAL AND PATHOLOGICAL CHANGES IN THE VITREORETINAL INTERFACE
- •BLOOD–RETINAL BARRIER
- •TIGHT JUNCTIONS
- •BLOOD–RETINA BARRIER DISRUPTION
- •MECHANISMS OF RETINAL ARTERIOLAR CALIBER CHANGES
- •MECHANISMS OF RETINAL VENULAR CALIBER CHANGES
- •MACULAR PIGMENTS
- •FUNCTIONS OF MACULAR PIGMENTS
- •Antioxidant
- •Optical filter
- •VISUAL CYCLE
- •RETINOID CYCLE
- •Outer segment of photoreceptors
- •Retinal pigment epithelium
- •Re-entry into the outer segment
- •Chaperones
- •PHOTOTRANSDUCTION
- •Activation
- •Inactivation
- •RETINAL PIGMENT EPITHELIUM AND LIPOFUSCIN
- •RETINAL PIGMENT EPITHELIUM
- •LIPOFUSCIN
- •Formation of lipofuscin
- •Lipofuscin and RPE atrophy
- •Stargardt’s disease and lipofuscin
- •Age-related macular degeneration and lipofuscin
- •MATRIX BIOLOGY
- •STRUCTURAL COMPOSITION OF THE BRUCH’S MEMBRANE
- •MACROSCOPIC CHANGES OF THE BRUCH’S MEMBRANE
- •CELL BIOLOGY OF BRUCH’S MEMBRANE
- •LIPID ACCUMULATION
- •MATRIX DYSREGULATION
- •MATRIX METALLOPROTEINASES
- •PHARMACOTHERAPY IMPLICATIONS
- •REFERENCES
- •INTRODUCTION
- •PROMOTERS OF ANGIOGENESIS
- •VEGF in physiologic and pathologic angiogenesis
- •Investigational approaches to VEGF inhibition in ocular neovascularization
- •RNA interference
- •Soluble VEGFR fusion protein: VEGF-Trap
- •Anecortave acetate
- •PLATELET-DERIVED GROWTH FACTOR
- •FIBROBLAST GROWTH FACTOR 2 (FGF2)
- •TUMOR NECROSIS FACTOR-α (TNF-α)
- •EPHS AND EPHRINS
- •NOTCH
- •ANGIOPOIETINS
- •Angiopoietin 1
- •Angiopoietin 2
- •ERYTHROPOIETIN
- •MATRIX METALLOPROTEINASES
- •INTEGRINS
- •COMPONENTS OF THE COMPLEMENT CASCADE
- •INHIBITORS OF ANGIOGENESIS
- •PIGMENT EPITHELIUM-DERIVED FACTOR
- •SOLUBLE VEGF RECEPTOR 1
- •VEGFXXXb ISOFORMS
- •COMPLEMENTARY REGULATORY PROTEIN C59
- •TRYPTOPHANYL-tRNA SYNTHASE FRAGMENT
- •OTHER INHIBITORS
- •SUMMARY
- •REFERENCES
- •Ocular immunity and inflammation
- •INTRODUCTION
- •HISTORY
- •KEY CONCEPTS AND FUNDAMENTALS IN MOLECULAR BIOLOGY AND BIOCHEMISTRY
- •INNATE IMMUNITY
- •ADAPTIVE IMMUNITY
- •MECHANISMS OF PATHOGENESIS
- •NONINFECTIOUS POSTERIOR AND PANUVEITIS
- •INFECTIOUS RETINITIS AND CHOROIDITIS
- •AGE-RELATED MACULAR DEGENERATION
- •DIABETIC RETINOPATHY
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •INTRODUCTION
- •HISTORY
- •KEY CONCEPTS IN COMPLEMENT BIOLOGY
- •SUMMARY
- •REFERENCES
- •Genetics of retinal disease
- •INTRODUCTION
- •HISTORY OF RETINAL GENE DISCOVERY
- •KEY CONCEPTS AND FUNDAMENTS OF GENETIC METHODS IN THE STUDY OF RETINAL DISEASE
- •GENETICS: ILLUMINATING MECHANISMS OF PATHOGENESIS, REVEALING COMPLEXITY
- •RP: A “COMPLEX” MONOGENIC DISEASE
- •SHEDDING LIGHT ON AMD
- •DELIVERY OF GENES TO TARGET PATHOGENIC PATHWAYS
- •GENE-INDEPENDENT THERAPY
- •SUMMARY: THE FUTURE IS BRIGHT
- •REFERENCES
- •SECTION 2: Animal Models and Routes for Retinal Drug Delivery
- •Vitamins and supplements for age-related macular degeneration
- •INTRODUCTION
- •HISTORY
- •KEY CONCEPTS AND PHARMACOLOGY OF CURRENT DIETARY SUPPLEMENTS
- •EPIDEMIOLOGIC DATA OF ASSOCIATION OF FAT AND ω-3 LCPUFAs WITH AMD
- •AVAILABLE SUPPLEMENTS FOR MACULAR DEGENERATION
- •IMPLICATIONS OF RETINAL SUPPLEMENT PHARMACOLOGY
- •FUTURE DIRECTIONS: AREDS2
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •Ocular pharmacokinetic, drug bioavailability, and intraocular drug delivery systems
- •INTRODUCTION
- •INTRAVITREAL ADMINISTRATION
- •OCULAR PHARMACOKINETICS
- •TOPICAL FORMULATIONS
- •CONVENTIONAL FORMULATIONS
- •INTRAOCULAR DRUG DELIVERY SYSTEMS
- •NONBIODEGRADABLE IMPLANTS
- •INTRAOCULAR BIODEGRADABLE DRUG DELIVERY SYSTEMS
- •ACKNOWLEDGMENTS
- •REFERENCES
- •INTRODUCTION
- •THE RATIONALE FOR INTRAVITREAL DRUG DELIVERY
- •HISTORY
- •KEY CONCEPTS AND FUNDAMENTAL POINTS IN RETINAL DRUG DELIVERY
- •STRATEGIES AND IMPLICATIONS FOR RETINAL PHARMACOTHERAPY
- •PREOPERATIVE PREPARATION
- •PROPHYLAXIS OF ENDOPHTHALMITIS: LOCAL DISINFECTION AND TOPICAL ANTIBIOTIC THERAPY
- •LOCAL TOPICAL ANESTHESIA
- •SURGICAL TECHNIQUES FOR RETINAL DRUG DELIVERY
- •THE PROCEDURE AND RECOMMENDED TECHNIQUE
- •COMPLICATIONS WITH THE ROUTE FOR DRUG DELIVERY
- •OCULAR COMPLICATIONS
- •PHARMACOKINETICS AND CLEARANCE OF INTRAVITREAL DRUGS
- •PHARMACOKINETICS OF INTRAVITREAL CRYSTALLINE TRIAMCINOLONE ACETONIDE
- •CLINICAL EXPERIENCE AND RESULTS IN VITRECTOMIZED, AIR-FILLED, OR SILICONE OIL EYES
- •VITRECTOMIZED EYES
- •Silicone oil tamponade
- •Gas tamponade
- •PREOPERATIVE DRUG APPLICATIONS
- •INTRAOPERATIVE DRUG APPLICATIONS
- •POSTOPERATIVE DRUG APPLICATIONS
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •INTRODUCTION
- •HISTORY
- •KEY CONCEPTS
- •ANIMAL MODELS
- •DRUG DELIVERY MODALITIES
- •TOPICAL DRUG DELIVERY
- •TRANSSCLERAL DRUG DELIVERY
- •SUPRACHOROIDAL DRUG DELIVERY
- •INTRAVITREAL GAS-PHASE NANOPARTICLE DRUG DELIVERY
- •SUMMARY AND KEY POINTS
- •ACKNOWLEDGMENT
- •REFERENCES
- •INTRODUCTION
- •HISTORY
- •KEY CONCEPTS AND FUNDAMENTAL POINTS IN SUSTAINED-RELEASE DRUG DELIVERY
- •EXISTING SUSTAINED-RELEASE DRUG DEVICES
- •BIODEGRADABLE POLYMER IMPLANTS
- •LIPOSOME ENCAPSULATION
- •CELLULAR ENCAPSULATION
- •THE FUTURE
- •SUMMARY
- •ACKNOWLEDGMENT
- •REFERENCES
- •INTRODUCTION
- •PERMEATION BARRIERS AND ANATOMICAL CONSIDERATIONS
- •THEORETICAL BACKGROUND
- •CYCLODEXTRINS
- •ANIMAL TESTING OF ROUTES OF DRUG DELIVERY
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •Thermo-sensitive hydrogels
- •INTRODUCTION
- •DELIVERY CHARACTERISTICS
- •POTENTIAL DELIVERY SITE
- •TOXICITY TESTING
- •FUTURE DIRECTION
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •Retina and ocular toxicity to ocular application of drugs
- •INTRODUCTION
- •HISTORY
- •MAJOR CLASSES OF DRUGS AND THEIR SAFETY PROFILE AFTER LOCAL OCULAR APPLICATION FOR RETINA THERAPY
- •CORTICOSTEROIDS
- •ANTIBIOTICS
- •NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
- •ENZYMES AND FIBRINOLYTICS
- •MISCELLANEOUS ANTI-INFLAMMATORY AND ANTIANGIOGENIC AGENTS
- •Summary and Key points
- •ACKNOWLEDGMENTS
- •REFERENCES
- •INTRODUCTION
- •KEY CONCEPTS AND FUNDAMENTALS
- •PHARMACOLOGY, BIOCHEMISTRY, AND TYPE OF IMPACT ON THE RETINA
- •DISRUPTION OF THE RETINA AND RETINAL PIGMENT EPITHELIUM
- •Phenothiazines
- •Thioridazine
- •Chlorpromazine
- •Chloroquine derivatives
- •Chloroquine
- •Hydroxychloroquine
- •Quinine sulfate
- •Clofazimine
- •2′,3′-dideoxyinosine (DDI)
- •Deferoxamine
- •Corticosteroid preparations
- •Cisplatin and BCNU (carmustine)
- •Potassium iodate
- •VASCULAR DAMAGE OR OCCLUSION
- •Quinine sulfate
- •Cisplatin and BCNU (carmustine)
- •Talc
- •Oral contraceptives
- •Aminoglycoside antibiotics
- •Interferon
- •Miscellaneous agents
- •CYSTOID MACULAR EDEMA AND RETINAL EDEMA/FOLDS
- •CYSTOID MACULAR EDEMA
- •Epinephrine and dipivefrin
- •Nicotinic acid
- •Prostaglandin analogues
- •Retinal edema/folds
- •Sulfa antibiotics, acetazolamide, ethoxyzolamide, chlorthalidone, hydrochlorothiazide, triamterene, metronidazole
- •Topiramate
- •CRYSTALLINE RETINOPATHY
- •TAMOXIFEN
- •CANTHAXANTHINE
- •METHOXYFLURANE
- •TALC
- •NITROFURANTOIN
- •UVEITIS
- •RIFABUTIN
- •CIDOFOVIR
- •LATANOPROST
- •CARDIAC GLYCOSIDES
- •SILDENAFIL
- •METHANOL
- •VIGABATRIN
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •INTRODUCTION
- •DISEASE PREVALENCE AND INFLUENCE
- •RISK FACTORS
- •ETIOLOGY/PATHOGENESIS
- •SIGNS AND SYMPTOMS
- •TREATMENT OPTIONS
- •VITAMIN C
- •CAROTENOIDS
- •VITAMIN E
- •MINERALS
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •Neovascular age-related macular degeneration
- •DISEASE PREVALENCE AND INFLUENCE
- •RISK FACTORS
- •ETIOLOGY/PATHOGENESIS
- •NATURAL HISTORY
- •NONPHARMACOLOGIC THERAPIES
- •PHARMACOLOGIC THERAPIES
- •PDT WITH VERTEPORFIN
- •PEGAPTANIB
- •RANIBIZUMAB
- •BEVACIZUMAB
- •COMBINATION THERAPY
- •TREATMENTS UNDER INVESTIGATION
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •Diabetic retinopathy and diabetic macular edema
- •INTRODUCTION
- •DIABETIC RETINOPATHY PREVALENCE
- •RISK FACTORS
- •ETIOLOGY AND PATHOGENESIS
- •SIGNS AND SYMPTOMS
- •TREATMENT OPTIONS
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •Retinal vein occlusion
- •INTRODUCTION
- •DISEASE PREVALENCE
- •RISK FACTORS
- •PATHOGENESIS
- •CENTRAL RETINAL VEIN OCCLUSION
- •BRANCH RETINAL VEIN OCCLUSION
- •TREATMENT OPTIONS
- •CENTRAL RETINAL VEIN OCCLUSION
- •BRANCH RETINAL VEIN OCCLUSION
- •TREATMENT OUTCOMES AND PROGNOSIS
- •CENTRAL RETINAL VEIN OCCLUSION
- •TISSUE PLASMINOGEN ACTIVATOR (tPA)
- •CORTICOSTEROIDS
- •BEVACIZUMAB
- •OTHER MEDICATIONS
- •Ranimizumab
- •Coumadin (warfarin)
- •Urokinase
- •Troxerutin
- •Ticlodipine
- •Pentoxifylline
- •Hemodilution
- •Laser treatment
- •Chorioretinal venous anastomosis
- •SURGICAL TREATMENT OF CRVO
- •Radial optic neurotomy (ron)
- •Branch retinal vein occlusion
- •Corticosteroids
- •Bevacizumab
- •Ranimizumab
- •Laser treatment
- •SURGICAL TREATMENT OF BRVO
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •Retinal detachment and proliferative vitreoretinopathy
- •INTRODUCTION
- •INCIDENCE OF RETINAL DETACHMENT
- •ETIOLOGY AND RISK FACTORS FOR RETINAL DETACHMENT
- •RISK FACTORS FOR PROLIFERATIVE VITREORETINOPATHY
- •SIGNS, SYMPTOMS, AND DIAGNOSIS
- •TREATMENT OPTIONS
- •PROGNOSIS WITH THE VARIOUS TREATMENT OPTIONS
- •ADJUNCTIVE THERAPIES
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •Posterior Uveitis
- •INTRODUCTION
- •DISEASE PREVALENCE AND INFLUENCE
- •RISK FACTORS
- •PATHOGENESIS
- •SPECIFIC DISEASES: DIAGNOSIS AND PHARMACOTHERAPY
- •ADAMANTIADES–BEHÇET DISEASE
- •Diagnostic features
- •Treatment modalities
- •BIRDSHOT RETINOCHOROIDOPATHY
- •Diagnostic features
- •Treatment modalities
- •Treatment modalities
- •SARCOIDOSIS
- •Diagnostic features
- •Treatment modalities
- •SERPIGINOUS CHOROIDOPATHY
- •Diagnostic features
- •Treatment modalities
- •VOGT–KOYANAGI–HARADA SYNDROME
- •Diagnostic features
- •Treatment modalities
- •SYMPATHETIC OPHTHALMIA
- •Diagnostic features
- •Treatment modalities
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •INTRODUCTION
- •DISEASE PREVALENCE
- •RISK FACTORS
- •MYOPIA
- •PRESUMED OCULAR HISTOPLASMOSIS SYNDROME
- •OTHER INFLAMMATORY CAUSES
- •ANGIOID STREAKS
- •IDIOPATHIC CNV
- •ETIOLOGY AND PATHOGENESIS
- •DIAGNOSIS AND ANCILLARY TESTING
- •MYOPIA
- •PRESUMED OCULAR HISTOPLASMOSIS SYNDROME
- •ANGIOID STREAKS
- •INFLAMMATORY CAUSES
- •DIFFERENTIAL DIAGNOSIS
- •CLINICAL SIGNS AND SYMPTOMS
- •MYOPIA
- •PRESUMED OCULAR HISTOPLASMOSIS SYNDROME
- •ANGIOID STREAKS
- •INFLAMMATORY CAUSES
- •TREATMENT
- •PHOTODYNAMIC THERAPY
- •SURGICAL THERAPY
- •ANTIANGIOGENIC THERAPY
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •INTRODUCTION
- •DISEASE INCIDENCE
- •RISK FACTORS
- •ETIOLOGY/PATHOGENESIS
- •SIGNS AND SYMPTOMS
- •OCULAR
- •SYSTEMIC
- •TREATMENT OPTIONS
- •SUMMARY AND KEY POINTS
- •ACKNOWLEDGMENTS
- •REFERENCES
- •Retinopathy of prematurity
- •INTRODUCTION
- •DISEASE PREVALENCE AND INFLUENCE
- •RISK FACTORS
- •ETIOLOGY/PATHOGENESIS
- •ABNORMAL RETINAL VASCULARIZATION IN ROP
- •ROLE OF GROWTH FACTORS IN ROP
- •DIAGNOSIS AND ANCILLARY TESTING/DIFFERENTIAL DIAGNOSIS
- •SIGNS AND SYMPTOMS
- •CLASSIFICATION OF RETINOPATHY OF PREMATURITY
- •TREATMENT OPTIONS FOR RETINOPATHY OF PREMATURITY
- •CRYOTHERAPY AND LASER THERAPY
- •INTRAVITREAL ANTI-VEGF THERAPY FOR ROP
- •Rationale for Treatment
- •Injection Technique
- •Patients
- •Results
- •Other Reported Results
- •Concerns with Intravitreal Anti-VEGF Therapy for ROP
- •Ocular complications
- •Systemic Complications
- •Vitrectomy
- •SUMMARY
- •REFERENCES
- •Idiopathic macular telangiectasia
- •INTRODUCTION
- •THERAPY
- •NONPROLIFERATIVE STAGE
- •PROLIFERATIVE STAGE
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •Neovascular glaucoma
- •INTRODUCTION
- •DISEASE PREVALENCE AND INFLUENCE
- •RISK FACTORS
- •ETIOLOGY/PATHOGENESIS
- •CENTRAL RETINAL VEIN OCCLUSION
- •DIABETIC RETINOPATHY
- •DIABETIC NEOVASCULAR GLAUCOMA
- •CAROTID ARTERY OCCLUSIVE DISEASE
- •CENTRAL RETINAL ARTERY OCCLUSION
- •INTRAOCULAR TUMORS
- •Malignant melanoma
- •Retinoblastoma
- •MISCELLANEOUS CAUSES
- •DIAGNOSIS AND ANCILLARY TESTING
- •DIFFERENTIAL DIAGNOSIS
- •SIGNS AND SYMPTOMS
- •TREATMENT OPTIONS
- •TREATMENT OF THE UNDERLYING DISEASE ASSOCIATED WITH NVG
- •Central retinal vein occlusion
- •Diabetic retinopathy
- •Carotid artery occlusive disease
- •Central retinal artery occlusion
- •PHARMACOLOGIC THERAPIES
- •Medical treatment to control high IOP
- •Anti-VEGF therapy
- •Corticosteroid therapy
- •Photodynamic therapy
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •INTRODUCTION
- •SPECIFIC DISEASES
- •RETINITIS PIGMENTOSA
- •Nutrients and retinitis pigmentosa
- •Cystoid Macular Edema (CME) associated with RP
- •Ciliary Neurotrophic Factor and retinitis pigmentosa
- •REFSUM’S DISEASE
- •Treatment
- •Dietary restriction
- •Plasmapheresis
- •GYRATE ATROPHY
- •Treatment
- •Arginine-restricted diet
- •Vitamin B6 supplementation
- •ABETALIPOPROTEINEMIA (BASSEN–KORNZWEIG SYNDROME)
- •Treatment
- •LEBER CONGENITAL AMAUROSIS
- •Treatment
- •RPE65 gene therapy
- •X-LINKED JUVENILE RETINOSCHISIS
- •Treatment
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •SECTION 4: Drugs and Mechanisms in Retinal Diseases
- •Nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of retinal diseases
- •KEY FEATURES
- •INTRODUCTION AND HISTORY
- •PHARMACOLOGY, DRUG MECHANISM, AND EFFECTS
- •DICLOFENAC
- •KETOROLAC
- •NEVANAC
- •BROMFENAC
- •DICLOFENAC
- •KETOROLAC
- •NEPAFENAC
- •BROMFENAC
- •CONTRAINDICATIONS, COMPLICATIONS, AND TOXICITY
- •SUMMARY AND KEY POINTS
- •ACKNOWLEDGMENTS
- •REFERENCES
- •KEY FEATURES
- •INTRODUCTION
- •PHARMACOLOGY
- •STRUCTURE
- •METABOLISM
- •Dexamethasone
- •Fluocinolone
- •CYSTOID MACULAR EDEMA
- •DIABETIC MACULAR EDEMA
- •RETINAL VEIN OCCLUSION
- •EXUDATIVE AGE-RELATED MACULAR DEGENERATION (AMD)
- •Raised intraocular pressure
- •Infectious, sterile, and pseudoendophthalmitis associated with triamcinolone acetonide
- •Cataract
- •Retinal detachment
- •FUTURE CONSIDERATIONS AND ONGOING STUDIES
- •THE SCORE STUDY
- •STEROID-SUSTAINED RELEASE DEVICES
- •The STRIDE study
- •FLUOCINOLONE ACETONIDE DEVICE
- •NEW-GENERATION FLUOCINOLONE DEVICE
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •Anecortave acetate
- •KEY FEATURES
- •INTRODUCTION AND HISTORY
- •PHARMACOLOGY
- •DRUG MECHANISM
- •DRUG EFFECTS IN RETINAL DISEASES
- •PRECLINICAL STUDIES
- •Retinopathy of prematurity
- •Intraocular tumors
- •Choroidal neovascularization
- •CLINICAL STUDIES
- •Exudative AMD
- •Other diseases
- •EFFICACY AND COMPARISON WITH OTHER AGENTS
- •CONTRAINDICATIONS
- •OCULAR COMPLICATIONS AND TOXICITY
- •SYSTEMIC COMPLICATIONS AND TOXICITY
- •DRUG INTERACTIONS
- •SUMMARY AND KEY POINTS
- •ACKNOWLEDGMENTS
- •REFERENCES
- •KEY FEATURES
- •INTRODUCTION AND HISTORY
- •PHARMACOLOGY
- •DRUG MECHANISM
- •DRUG USE IN RETINAL DISEASES
- •AGE-RELATED MACULAR DEGENERATION
- •DIABETIC RETINOPATHY
- •RETINAL VEIN OCCLUSION (RVO)
- •UVEITIC CYSTOID MACULAR EDEMA (CME)
- •RETINOPATHY OF PREMATURITY (ROP)
- •RETINAL TELANGIECTASIAS
- •NEOVASCULAR GLAUCOMA (NVG)
- •OTHERS
- •CONTRAINDICATIONS
- •OCULAR COMPLICATIONS AND TOXICITY
- •SYSTEMIC COMPLICATION AND TOXICITY
- •DRUG INTERACTIONS
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •KEY FEATURES
- •INTRODUCTION AND HISTORY
- •PHARMACOLOGY
- •PHARMACOLOGICAL DESIGN
- •PHARMACOKINETICS
- •PHARMACODYNAMICS
- •DRUG MECHANISM
- •DRUG USE IN RETINAL DISEASES
- •EFFICACY
- •EFFICACY IN AMD
- •EFFICACY IN OTHER RETINAL DISEASES
- •CONTRAINDICATIONS
- •OCULAR COMPLICATIONS AND TOXICITY
- •DRUG INTERACTIONS
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •Pathophysiology of vascular endothelial growth factor and other angiogenic molecules
- •KEY FEATURES
- •INTRODUCTION
- •BIOLOGICAL EFFECTS OF VEGF-A
- •VEGF-A ISOFORMS
- •VEGF RECEPTORS
- •ROLE OF VEGF-A IN INTRAOCULAR NEOVASCULAR SYNDROMES
- •INTRAVITREAL ANTI-VEGF THERAPY FOR NEOVASCULAR AMD: PEGAPTANIB, RANIBIZUMAB AND BEVACIZUMAB
- •OTHER ANTI-VEGF THERAPIES IN CLINICAL DEVELOPMENT FOR AMD
- •OTHER ANGIOGENIC FACTORS
- •FIBROBLAST GROWTH FACTOR FAMILY
- •PLACENTAL GROWTH FACTOR
- •DELTA-LIKE LIGAND 4
- •SUMMARY AND KEYPOINTS
- •REFERENCES
- •KEY FEATURES
- •INTRODUCTION
- •TUMOR NECROSIS FACTOR-ALPHA ANTAGONISTS
- •INFLIXIMAB (REMICADE)
- •Pharmacology and mechanism
- •Systemic indications for infliximab
- •Ophthalmic indications for infliximab
- •Contraindications
- •Ocular complications and toxicity
- •Systemic complications and toxicity
- •Drug interactions
- •Summary
- •ADALIMUMAB (HUMIRA)
- •Pharmacology and mechanism
- •Systemic indications
- •Ophthalmic indications
- •Contraindications
- •Ocular toxicity
- •Systemic toxicity
- •Drug interactions
- •Summary
- •ETANERCEPT (ENBREL)
- •Pharmacology and mechanism
- •Systemic indications
- •Ophthalmic indications
- •Contraindications
- •Ocular toxicity
- •Systemic toxicity
- •Drug interactions
- •Summary
- •INTERLEUKIN-2 RECEPTOR ANTAGONIST
- •DACLIZUMAB (ZENAPAX)
- •Pharmacology and mechanism
- •Systemic indication
- •Ophthalmic indications
- •Contraindications
- •Ocular toxicity
- •Systemic toxicity
- •Drug interactions
- •Summary
- •OTHER BIOLOGIC AGENTS
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •KEY FEATURES
- •CALCINEURIN INHIBITORS
- •CICLOSPORIN (CYCLOSPORIN: CsA)
- •Key features, introduction, and history
- •Pharmacology
- •Drug effects in human nonocular diseases
- •Drug use in retinal diseases
- •Pediatric case series
- •EFFICACY AND COMPARISON WITH OTHER AGENTS
- •Ciclosporin versus tacrolimus
- •TACROLIMUS
- •Key features, introduction, and history
- •Pharmacology
- •Drug effects in human nonocular diseases
- •Drug use in retinal diseases
- •Summary and key points
- •ANTIMETABOLITES
- •MYCOPHENOLATE MOFETIL (MMF)
- •Key features, introduction, and history
- •Pharmacology
- •Drug mechanism
- •Drug effects in human nonocular diseases
- •Drug use in retinal diseases
- •Pediatric case series
- •METHOTREXATE
- •Key features, introduction, and history
- •Pharmacology
- •Drug mechanism
- •Drug effects in human nonocular diseases
- •Drug use in retinal diseases
- •Pediatric case series
- •Intravitreal methotrexate injection
- •AZATHIOPRINE
- •Key features, introduction, and history
- •Pharmacology
- •Drug mechanism
- •Drug effects in human nonocular diseases
- •Drug use in retinal diseases
- •Pediatric case series
- •Summary and key points
- •ALKYLATING AGENTS
- •CYCLOPHOSPHAMIDE
- •Key features, introduction, and history
- •Pharmacology
- •Drug effects in human nonocular diseases
- •Drug use in retinal diseases
- •Efficacy and comparison with other agents
- •CHLORAMBUCIL
- •Key features, introduction, and history
- •Pharmacology
- •Drug effects in human nonocular diseases
- •Drug use in retinal diseases
- •Efficacy and comparison with other agents
- •Summary and key points
- •SUMMARY
- •REFERENCES
- •KEY FEATURES
- •INTRODUCTION AND HISTORY
- •PHARMACOLOGY
- •DRUG MECHANISM
- •DRUG EFFECTS IN PRECLINICAL MODELS
- •SYSTEMIC AND OCULAR COMPLICATIONS AND TOXICITY
- •BIOACTIVITY IN HUMAN EYE DISEASES
- •NEOVASCULAR AMD PHASE I
- •NEOVASCULAR AMD PHASE III PROGRAM
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •KEY FEATURES
- •INTRODUCTION AND HISTORY
- •PHARMACOLOGY
- •PHARMACOKINETICS
- •DRUG MECHANISM
- •DRUG USE IN RETINAL DISEASES
- •DIABETIC RETINOPATHY
- •RETINAL VEIN OCCLUSION
- •OTHERS
- •CONTRAINDICATIONS
- •OCULAR COMPLICATIONS AND TOXICITY
- •DRUG INTERACTIONS
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •KEY FEATURES
- •INTRODUCTION TO PROTEIN KINASE C
- •PROTEIN KINASE C FAMILY
- •EFFECTS OF ACTIVATED PKC
- •PHARMACOLOGY OF RUBOXISTAURIN
- •EFFECT OF RUBOXISTAURIN IN HUMAN NONOCULAR DISEASES
- •Use of PKC Inhibitors in the treatment of diabetic macular edema and diabetic retinopathy
- •EFFICACY OF RUBOXISTAURIN IN THE TREATMENT OF DIABETIC RETINOPATHY
- •OCULAR AND SYSTEMIC COMPLICATIONS AND TOXICITY OF RUBOXISTAURIN
- •INTERACTION OF RUBOXISTAURIN WITH OTHER DRUGS
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •KEY FEATURES
- •INTRODUCTION AND HISTORY OF SIRNA FOR RETINAL DISEASES
- •PHARMACOLOGY, DRUG MECHANISM, AND DRUG EFFECTS IN NONOCULAR DISEASES
- •DRUG USES IN RETINAL DISEASES
- •BEVASIRANIB FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION
- •BEVASIRANIB FOR NEOVASCULAR MACULAR DEGENERATION: RESULTS
- •BEVASIRANIB FOR THE TREATMENT OF DIABETIC MACULAR EDEMA (DME)
- •SIRNA-027 FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION
- •REDD14 NP
- •SUMMARY AND KEY POINTS
- •ACKNOWLEDGMENT
- •REFERENCES
- •Ocular gene therapy
- •KEY FEATURES
- •INTRODUCTION TO GENE THERAPY
- •CURRENT VIRAL VECTORS
- •VIRAL VECTOR-ASSOCIATED RISKS
- •VIRAL VERSUS NONVIRAL VECTORS
- •STRATEGIES FOR RECESSIVE VERSUS DOMINANT DISEASE
- •STRATEGIES FOR PROLIFERATIVE AND NEOPLASTIC OCULAR DISEASE
- •RETINOBLASTOMA GENE THERAPY CLINICAL TRIAL
- •GENE THERAPY FOR LEBER’S CONGENITAL AMAUROSIS TRIAL
- •SUMMARY AND KEYPOINTS: THE FUTURE OF GENE THERAPY
- •REFERENCES
- •KEY FEATURES
- •INTRODUCTION
- •MECHANISM OF PROTECTION: APPROACHES AND CHALLENGES
- •ANTIOXIDATIVE THERAPY
- •EXCITOTOXICITY
- •NEUROTROPHIC FACTORS
- •ANTIAPOPTOPIC THERAPY
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •KEY FEATURES
- •INTRODUCTION AND HISTORY
- •PHARMACOLOGY
- •DRUG MECHANISM
- •PDT IN ONCOLOGICAL DISORDERS
- •PDT IN IMMUNE (NONONCOLOGICAL) DISORDERS
- •DRUG USE IN RETINAL DISEASES
- •AGE-RELATED MACULAR DEGENERATION
- •PATHOLOGIC MYOPIA
- •OTHER SUBFOVEAL AND JUXTAFOVEAL POSTINFLAMMATORY OR IDIOPATHIC CHOROIDAL NEOVASCULARIZATION
- •POLYPOIDAL CHOROIDAL VASCULOPATHY
- •CENTRAL SEROUS CHORIORETINOPATHY
- •INTRAOCULAR VASOPROLIFERATIVE TUMORS
- •RETINAL ASTROCYTOMA
- •CHOROIDAL OSTEOMA
- •CHOROIDAL MELANOMA
- •RETINOBLASTOMA
- •CONJUNCTIVAL IN SITU SQUAMOUS CELL CARCINOMA
- •EFFICACY AND COMPARISON WITH OTHER AGENTS
- •CONTRAINDICATIONS
- •OCULAR COMPLICATIONS AND TOXICITY
- •DRUG INTERACTIONS
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •KEY FEATURES
- •INTRODUCTION
- •RETINOBLASTOMA (Tables 44.1 and 44.2)
- •GENERAL CONSIDERATIONS
- •CHEMOREDUCTION
- •AGENTS
- •RESULTS
- •CHEMOREDUCTION FAILURE
- •SIDE-EFFECTS
- •CHEMOTHERMOTHERAPY
- •PERIOCULAR AND SUBCONJUNCTIVAL CHEMOTHERAPY
- •INTRAVITREAL CHEMOTHERAPY
- •INTRA-ARTERIAL CHEMOTHERAPY
- •ADJUVANT CHEMOTHERAPY
- •NO CHOROIDAL, SCLERAL, OR POSTLAMINAR OPTIC NERVE INVOLVEMENT
- •CHOROIDAL INVASION
- •POSTLAMINAR OPTIC NERVE INVASION
- •TUMOR AT CUT OPTIC NERVE MARGIN
- •METASTATIC RETINOBLASTOMA
- •UVEAL METASTASIS
- •GENERAL CONSIDERATIONS
- •CHEMOTHERAPY
- •PROGNOSIS
- •UVEAL MELANOMA
- •METASTATIC UVEAL MELANOMA
- •INTRAOCULAR LYMPHOMA
- •GENERAL CONSIDERATIONS
- •TREATMENT
- •SUMMARY AND KEYPOINTS
- •REFERENCES
- •Antibiotics
- •INTRODUCTION
- •POTENTIAL NEW TREATMENT REGIMENS
- •TOPICAL FLUOROQUINOLONES
- •ORAL AND INTRAVENOUS ANTIBIOTICS
- •NASALLY APPLIED ANTIBIOTICS
- •ORAL, TOPICAL, AND INTRAVITREAL ANTIFUNGAL AGENTS
- •CONCLUSION
- •REFERENCES
- •SECTION 5: Pharmacotherapy and Surgery
- •KEY FEATURES (PHARMACOLOGY)
- •INTRODUCTION AND HISTORY
- •RHEOPHERESIS IN RETINAL DISEASES
- •AGE-RELATED MACULAR DEGENERATION
- •MAC-1 trial
- •Multicenter investigation of rheopheresis for AMD (MIRA-1)
- •DIABETIC MACULOPATHY
- •CENTRAL RETINAL VEIN OCCLUSION
- •UVEAL EFFUSION SYNDROME
- •Complications
- •SUMMARY
- •REFERENCES
- •Enzymatic vitrectomy and pharmacologic vitreodynamics
- •INTRODUCTION AND HISTORY
- •PHARMACOLOGY AND BIOCHEMISTRY
- •INDICATIONS
- •SURGICAL ADJUNCT
- •NONSURGICAL INDICATIONS
- •OPERATIVE TECHNIQUES
- •OUTCOMES
- •SUMMARY
- •REFERENCES
- •KEY FEATURES, INTRODUCTION, AND HISTORY
- •RATIONALE
- •PHARMACOLOGY AND BIOCHEMISTRY
- •INDICATIONS, OUTCOMES, AND COMPLICATIONS – VITAL DYES IN CHROMOVITRECTOMY
- •INDOCYANINE GREEN
- •INFRACYANINE GREEN
- •TRYPAN BLUE
- •PATENT BLUE
- •BRILLIANT BLUE
- •SODIUM FLUORESCEIN (SF)
- •TRIAMCINOLONE ACETONIDE
- •DYE INJECTION
- •MACULAR HOLE PROTECTION
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •KEY FEATURES
- •INTRODUCTION AND HISTORY
- •BIOLOGICAL EFFECTS
- •INDICATIONS
- •CHOROIDAL MELANOMA
- •OTHER OCULAR TUMORS
- •OPERATIVE TECHNIQUES
- •PLAQUE PLACEMENT TECHNIQUE
- •EPIMACULAR BRACHYTHERAPY FOR AGE-RELATED MACULAR DEGENERATION
- •SURGICAL TECHNIQUE
- •OUTCOMES
- •CHOROIDAL MELANOMA
- •BRACHYTHERAPY FOR AGE-RELATED MACULAR DEGENERATION
- •COMPLICATIONS
- •RADIATION RETINOPATHY
- •OPTIC NEUROPATHY
- •LENS TOXICITY
- •SCLERA/CHOROID TOXICITY
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •INTRODUCTION
- •RPE DISEASE AND INDICATIONS FOR TREATMENT BY TRANSPLANTATION
- •BRUCH’S MEMBRANE AS A SUBSTRATE FOR TRANSPLANTED RPE
- •HISTORICAL DEVELOPMENT OF RPE TREATMENT
- •AUTOLOGOUS TREATMENT
- •IRIS PIGMENT EPITHELIUM
- •RETINAL PIGMENT EPITHELIUM
- •Suspension
- •RPE-BM Choroid Sheet
- •TISSUE ENGINEERING AND RPE REPLACEMENT STRATEGIES
- •PROSTHESIS OR TISSUE ENGINEERING OF BRUCH’S MEMBRANE
- •STEM CELLS
- •Embryonic stem cells
- •Bone marrow-derived cells
- •MANAGING DECONSTRUCTIVE REACTIONS INDUCED BY RETINAL DETACHMENT
- •CONCLUSIONS AND FUTURE DIRECTIONS
- •ACKNOWLEDGMENTS
- •REFERENCES
- •SECTION 6: The Last Words
- •Off-label drugs and the impact of the Food and Drug Administration in the treatment of retinal disease
- •INTRODUCTION
- •OFF-LABEL DRUG USAGE AND THE FOOD AND DRUG ADMINISTRATION
- •HISTORICAL PERSPECTIVES
- •FDA APPROVAL PROCESS
- •THE CONCEPT OF “OFF-LABEL”
- •“INVESTIGATIONAL USAGE OF DRUGS”
- •COMPOUNDING PHARMACIES
- •RISK MANAGEMENT ISSUES
- •INFORMED CONSENT
- •MEDICAL PAYMENT/COVERAGE
- •NATIONAL COVERAGE DETERMINATION
- •CLINICAL TRIALS
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •INTRODUCTION
- •HISTORY
- •KEY CONCEPTS
- •EVIDENCE-BASED MEDICINE
- •TYPES OF PHARMACOECONOMIC ANALYSIS
- •COST MINIMIZATION ANALYSIS
- •COST–BENEFIT ANALYSIS
- •COST-EFFECTIVENESS ANALYSIS
- •Cost-effectiveness analysis
- •COST–UTILITY ANALYSIS
- •Quality of life: Function-based instruments
- •Quality of life: Preference-based instruments
- •Utility gain
- •Value gain
- •Value trumps cost
- •Cost–utility ratio
- •Cost-effectiveness standards
- •Discounting5
- •Value-based medicine
- •Standardization
- •Patient respondents
- •COST PERSPECTIVE
- •SUMMARY AND KEY POINTS
- •REFERENCES
- •Future perspectives:
- •INTRODUCTION
- •KEY FEATURES
- •ANGIOGENESIS AND NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
- •TYROSINE KINASE INHIBITORS
- •PDGF INHIBITORS
- •INTEGRIN INHIBITORS
- •SMALL INTERFERING RNA
- •BIOACTIVE LIPIDS
- •NONNEOVASCULAR AGE-RELATED MACULAR DEGENERATION
- •COMPLEMENT INHIBITORS
- •DIABETIC MACULAR EDEMA
- •INHIBITION OF INFLAMMATION
- •SUMMARY AND KEY POINTS
- •ACKNOWLEDGMENT
- •REFERENCES
- •Index
Commissioning Editor: Russell Gabbedy
Development Editor: Alexandra Mortimer
Editorial Assistant: Poppy Garraway
Project Manager: Beula Christopher
Design: Charles Gray
Illustration Manager: Gillian Richards
Illustrator: Cactus
Marketing Managers (UK/USA): Richard Jones / Helena Mutak
Retinal
Pharmacotherapy
Quan Dong Nguyen MD, MSc
Associate Professor of Ophthalmology
Diseases of the Retina and Vitreous, and Uveitis
Wilmer Eye Institute
Johns Hopkins University School of Medicine
Baltimore, MD, USA
Eduardo Büchele Rodrigues MD
Department of Ophthalmology
Vision Institute
Federal University of São Paulo
São Paulo, Brazil
Michel Eid Farah MD
Professor of Ophthalmology and Vice-chairman
Retina and Vitreous Department
Vision Institute
Federal University of São Paulo
São Paulo, Brazil
William F. Mieler MD
Professor and Vice-Chairman
Department of Ophthalmology & Visual Sciences
University of Illinois at Chicago
Chicago, IL, USA
SAUNDERS is an imprint of Elsevier Inc.
© 2010, Elsevier Inc. All rights reserved.
First published 2010
Chapter 35 in this publication is in the public domain and may be used and reprinted without special permission: citation of the source, however, is appreciated.
No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher’s permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/ permissions.
British Library Cataloguing in Publication Data
Retinal pharmacotherapy.
1. Retina–Diseases–Chemotherapy.
I. Rodrigues, Eduardo.
617.7′35061-dc22
ISBN-13: 9781437706031
Library of Congress Cataloging in Publication Data
A catalog record for this book is available from the Library of Congress
Notices
Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary. Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.
With respect to any drug or pharmaceutical products identified, readers are advised to check the most current information provided (i) on procedures featured or (ii) by the manufacturer of each product to be administered, to verify the recommended dose or formula, the method and duration of administration, and contraindications. It is the responsibility of practitioners, relying on their own experience and knowledge of their patients, to make diagnoses, to determine dosages and the best treatment for each individual patient, and to take all appropriate safety precautions.
To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.
The Publisher
|
|
|
|
The |
|
|
|
|
|
||
|
Working together to grow |
|
|||
|
|
publisher’s |
|||
|
libraries in developing countries |
|
policy is to use |
||
|
|
paper manufactured |
|||
|
www.elsevier.com | www.bookaid.org | www.sabre.org |
|
from sustainable forests |
||
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Printed in China |
|
|
|
||
Last digit is the print number: 9 8 7 6 5 4 |
3 2 1 |
||||
Foreword
During the past 25 years, our understanding of the molecular mechanisms of ocular diseases has greatly increased. As particular molecules have been implicated in disease processes, treatments that specifically target those molecules have been developed. Some recent successes have fueled research aimed at further elucidating molecular pathogenesis of ocular diseases and translational research aimed at converting recent findings into treatments. Those successes have also awakened the pharmaceutical industry to the unmet needs and potential opportunities related to ocular diseases. Thus, it is likely that new pharmacotherapies for retinal and uveal diseases will continue to become available for the foreseeable future.
In Retinal Pharmacotherapy, the editors, Quan Dong Nguyen, Eduardo Büchele Rodrigues, Michel Eid Farah, and William F. Mieler, and the authors have compiled a valuable resource that describes numerous pharmacologic agents that are currently available to treat retinal and posterior uveitic diseases. The Book is organized into six sections. Section 1 is devoted to the basic understanding of the molecular pathogenesis of retinal diseases. Section 2 describes animal models of retinal diseases that are useful for preclinical testing of drugs given by various routes of administration. Clinical features of retinal and
posterior uveitic diseases that may be amendable to pharmacotherapy are discussed in Section 3. In Section 4, the appropriate uses of several drugs that have been shown to have therapeutic benefits for retinal diseases are reviewed. Section 5 covers topics that combine pharmacotherapy and surgery for treatment of retinal and posterior uveal diseases. Section 6 discusses value-based medicine, pharmacoeconomics, and the impact of regulatory bodies such as the FDA in the development of pharmacotherapy for retinal diseases.
Retinal Pharmacotherapy contains 53 chapters with contributions from over 120 authors from North America, South America, Europe, Asia, and Australia, many of whom are recognized authorities in the field. It will serve as an important resource for retina specialists, uveitis specialists, and comprehensive ophthalmologists.
Peter A. Campochiaro, MD
George and Dolores Eccles Professor of Ophthalmology Wilmer Eye Institute
Johns Hopkins University 2009
ix
List of contributors
Anthony P Adamis MD
Adjunct Professor
Department of Ophthalmology and Visual
Sciences
University of Illinois College of Medicine
Chicago, IL, USA
Madeleine KM Adams MB ChB
BSc (Hons) MRCOphth
Honorary Research Fellow University of Melbourne
Centre for Eye Research Australia Royal Victorian Eye and Ear Hospital East Melbourne, VIC, Australia
Thomas A Albini MD
Assistant Professor of Clinical
Ophthalmology
Bascom Palmer Eye Institute
Miami, FL, USA
Jayakrishna Ambati MD
Professor and Vice Chair
Ophthalmology and Visual Sciences
Professor of Physiology
Dr. E. Vernon Smith and Eloise C. Smith
Endowed Chair
University of Kentucky
Doris Duke Distinguished Clinical
Scientist
Burroughs Wellcome Translational
Research Clinical Scientist
Lexington, KY, USA
Luis Amselem MD
Consultant, Institut de la Mácula i de la Retina
Consultant, Department of Ophthalmology and Visual Sciences Retinal and Vitreous Surgery Ocular Oncology
2nd Mayo Hospital Barcelona, Spain
J Fernando Arévalo MD, FACS
Professor of Ophthalmology
Clinica Oftalmologica Centro Caracas and University of Los Andes
The Arévalo-Coutinho Foundation for Research in Ophthalmology Caracas, Venezuela
Lluis Arias MD
Consultant
Institut de la Mácula i de la Retina Centro Médico Teknon Barcelona, Spain
Helen Dede Ayertey MD
Doctor of Medicine Center of Ophthalmology University of Cologne Cologne, Germany
Paul N Baird BSc (Hons) PhD
Associate Professor of Ophthalmology University of Melbourne
Centre for Eye Research Australia Royal Victorian Eye and Ear Hospital East Melbourne, VIC, Australia
Susanne Binder MD
Professor and Chairman Department of Ophthalmology The Ludwig Boltzmann Institute for
Retinology and Biomicroscopic Laser Surgery
Vienna, Austria
Fabio Bom Aggio MD
Vision Institute, Department of Ophthalmology
Federal University of São Paulo São Paulo, Brazil
Melissa M Brown MD, MN, MBA
Director, Center for Value-Based Medicine; Adjunct Senior Fellow, Leonard Davis Institute
Center for Value-Based Medicine Flourtown, PA, USA
Gary C Brown MD, MBA
Attending Surgeon Retina Service Wills Eye Institute
Chief Medical Officer
Center for Value-Based Medicine Wyndmoor, PA, USA
Richard Brunner MD
Professor of Ophthalmology
Center of Ophthalmology
University of Cologne
Cologne, Germany
J Peter Campbell MD, MPH
Resident in Ophthalmology
Wilmer Eye Institute
Johns Hopkins University School of
Medicine
Baltimore, MD, USA
Jose A Cardillo MD
Department of Ophthalmology
Federal University of São Paulo
UNIFESP-EPM
São Paulo, Brazil
Chi-Chao Chan MD
Chief, Section of Immunopathology
Laboratory of Immunology
Chief, Histology Core
National Eye Institute
National Institutes of Health
Bethesda, MD, USA
Pik Sha Chan MD
Attending Physician
Retina and Pediatric Ophthalmology
Service
Asian Eye Institute
Makati City, Philippines
Aimee v Chappelow MD
Cole Eye Institute
Cleveland Clinic Foundation
Cleveland, OH, USA
xi
contributors of List
Emily Y Chew MD
Deputy Director
Division of Epidemiology and Clinical
Applications
National Eye Institute
National Institutes of Health
Bethesda, MD, USA
Victor Chong MD
Consultant Ophthalmic Surgeon
University of Oxford
Oxford Eye Hospital
Oxford, UK
Hanna R Coleman MD
Staff Clinician, New York Presbyterian
Hospital, Columbia
Department of Ophthalmology
Columbia University Medical Center
NY, USA
Gabriel J Coscas MD
Emeritus Professor of Clinical
Ophthalmology
Department of Ophthalmology
University of Paris XII
Créteil, France
Yongping Crawford MD PhD
ES Cell Culture
Genentech, Inc.
San Francisco, CA, USA
Emmett T Cunningham Jr
MD PhD MPH
Director, The Uveitis Service
California Pacific Medical Center
Adjunct Clinical Professor of
Ophthalmology
Stanford University School of Medicine
San Francisco, CA, USA
Hajir Dadgostar MD
Cole Eye Institute
Cleveland Clinic Foundation
Cleveland, OH, USA
Taraprasad Das MD FRCS
Director
LV Prasad Eye Institute
Patia
Bhubaneswar, India
Janet l Davis MD MA
Professor of Ophthalmology
Department of Ophthalmology
Bascom Palmer Eye Institute
University of Miami
Miami, FL, USA
Heidrun L Deissler Dipl-Chem
Head of Research Laboratory
Department of Ophthalmology
University Eye Hospital Ulm
Ulm, Germany
Diana V Do MD
Assistant Professor of Ophthalmology
the Wilmer Eye Institute
the Johns Hopkins University School of
Medicine
Baltimore, MD, USA
Michel Eid Farah MD
Professor of Ophthalmology and
Vice-chairman
Retina and Vitreous Department
Federal University of São Paulo
Vision Institute
São Paulo, Brazil
Napoleone Ferrara MD
Genentech Fellow
Genentech, Inc.
San Francisco, CA, USA
Robert P Finger MD MIH
Department of Ophthalmology
University of Bonn
Bonn, Germany
Harry W Flynn, Jr. MD
The J Donald M Gass Distinguished
Chair in Ophthalmology
Professor of Ophthalmology
Bascom Palmer Eye Institute
University of Miami Miller School of
Medicine
Naples, FL, USA
Gildo y Fujii MD PhD
Professor of Ophthalmology
Londrina State University
Fujii Institute of Ophthalmology
Londrina, Brazil
Gerardo García-Aguirre MD
Assistant Staff Retina Department
Hospital “Dr. Luis Sánchez Bulnes” Asociación para Evitar la Ceguera en México (APEC)
Mexico City, Mexico
Thomas W Gardner MD MS
Jack and Nancy Turner Professor
of Ophthalmology and Cellular and
Molecular Physiology
Department of Ophthalmology
Penn State College of Medicine
Hershey, PA, USA
Gerhard Garhöfer MD
Department of Clinical Pharmacology
Medical University of Vienna
Vienna, Austria
Mauro Goldbaum MD
Executive Director
Eyetech, Inc
São Paulo, Brazil
David T Goldenberg MD
Private Practice
Retinal Consultants of Arizona
Phoenix, AZ, USA
Sandeep Grover MD
Assistant Professor
Director, Inherited Retinal Diseases and
Electrophysiology
Department of Ophthalmology
University of Florida
Jacksonville, FL, USA
Robyn H Guymer MBBS PhD FRANZCO
Professor of Ophthalmology University of Melbourne
Centre for Eye Research Australia Royal Victorian Eye and Ear Hospital East Melbourne, VIC, Australia
Zohar Habot-Wilner MD
Doctor of Medicine
Department of Ophthalmology
Tel-Aviv Medical Center
Tel-Aviv, Israel
Seenu M Hariprasad MD
Associate Professor of Surgery
Section of Ophthalmology and Visual
Science
Chief, Vitreoretinal Service
Director of Clinical Research and
Vitreoretinal Fellowship Program
University of Chicago
Chicago, IL, USA
Jeffrey S Heier MD
Vitreoretinal Specialist
Ophthalmic Consultants of Boston
Boston, MA, USA
xii
Rocío Herrero-Vanrell PhD
Professor of Pharmaceutical Technology
Department of Pharmacy and
Pharmaceutical Technology
School of Pharmacy
Universidad Complutense
Madrid, Spain
Alexandra A Herzlich MD
National Institute of Health
Bethesda, MD, USA
Frank G Holz MD
Ophthalmologist, University Eye Hospital
Director
Department of Ophthalmology
University of Bonn
Bonn, Germany
John j Huang MD
Assistant Professor
Director of Ocular Immunology and
Uveitis
Faculty of Vitreo-Retina
Director of Clinical Trials and
Translational Research
Department of Ophthalmology
Yale University
New Haven, CT, USA
Mohamed Ibrahim MD
Research Fellow
Wilmer Eye Institute
Johns Hopkins University School of
Medicine
Baltimore, MD, USA
Hisanori Imai MD
Department of Ophthalmology
Kobe University School of Medicine
Kobe, Japan
Peter Charbel Issa MD FEBO
Department of Ophthalmology
University of Bonn
Bonn, Germany
Peter K Kaiser MD
Professor of Ophthalmology
Cleveland Clinic Lerner College of
Medicine
Director, Digital OCT Reading Center
Cole Eye Institute
Cleveland, OH, USA
Jennifer J Kang-Mieler PhD
Associate Professor of Biomedical
Engineering
Department of Ophthalmology and Visual
Sciences
Illinois Institute of Technology
Chicago, IL, USA
Ravi Keshavamurthy MD
Retina Fellow
Department of Ophthalmology
University of Florida
Jacksonville, FL, USA
Bernd Kirchhof MD
Department of Vitreo-Retinal Surgery
Center of Ophthalmology
University of Cologne
Cologne, Germany
Ainat Klein MD
Medical Doctor
Department of Ophthalmology
Tel-Aviv Medical Center, Sackler Faculty
of Medicine
Tel-Aviv University
Tel-Aviv, Israel
Mark E Kleinman MD
Resident in Ophthalmology
Department of Ophthalmology and Visual
Sciences
University of Kentucky
Lexington, KY, USA
Tim U Krohne MD FEBO
Ophthalmologist
University Eye Hospital
Bonn, Germany
Baruch D Kuppermann MD PhD
Professor of Ophthalmology
University of California Irvine
Irvine, CA, USA
Malaika M Kurz-Levin MD
University Hospital
Department of Ophthalmology
Medical Retina
Zurich, Switzerland
Oh Woong Kwon MD PhD
Director
The Retina Center
Nune Eye Hospital
Seoul, South Korea
Gabriele E Lang MD
Professor of Ophthalmology
Head of the Division of Medical Retina
and Laser Surgery
Department of Ophthalmology
University Eye Hospital Ulm
Ulm, Germany
Susan Lightman PhD FRCP FRCOphth
Professor of Clinical Ophthalmology
Department of Clinical Opthalmology
Institute of Ophthalmology
Moorfields Eye Hospital
London, UK
Richard C Lin MD PhD
Clinical Assistant Professor
Stanford University
Palo Alto Veterans Hospital
Palo Alto, CA, USA
Anat Loewenstein MD
Professor of Ophthalmology
Department of Ophthalmology
Tel Aviv Medical Center
Tel Aviv, Israel
Thorsteinn Loftsson MSPharm PhD
Professor
Faculties of Medicine and Pharmacy
University of Iceland
Reykjavik, Iceland
Tao Lu Lowe PhD
Associate Professor of Pharmaceutical
Sciences
School of Pharmacy
Thomas Jefferson University
Philadelphia, PA, USA
Maurício Maia MD PhD
Professor of Vitreoretinal Surgery
Department of Ophthalmology
Federal University of São Paulo
São Paulo, Brazil
Juliana Mantovani Bottós MD
Vision Institute, Department of
Ophthalmology
Federal University of São Paulo
São Paulo, Brazil
Mariana Martínez-Castellanos
MD
Retina Department
Hospital “Dr. Luis Sánchez Bulnes”
Mexico City, Mexico
contributors of List
xiii
contributors of List
Trevor J McFarland BS
Senior Research Assistant
Casey Eye Institute
Oregon Health and Science University
Portland, OR, USA
Gustavo B Melo MD
Vision Institute, Department of
Ophthalmology
Federal University of São Paulo
São Paulo, Brazil
Carsten H Meyer MD
Ophthalmologist
University Eye Hospital
Bonn, Germany
Stephan Michels MD MBA
Assistant Professor of Medical Retina
Department of Ophthalmology
Triemli Hospital Zurich
Zurich, Switzerland
William F Mieler MD
Professor and Vice-Chairman
Department of Ophthalmology and Visual
Sciences
University of Illinois at Chicago
Chicago, IL, USA
Gauri P Misra MD
Department of Pharmaceutical Sciences
School of Pharmacy
Thomas Jefferson University
Philadelphia, PA, USA
Jordi M Monés MD
Director
Institut de la Mácula i de la retina Centro Médico Teknon Barcelona, Spain
Raja Narayanan MD
Consultant
Kanuri Santhamma Vitreoretinal Service
LV Prasad Eye Institute
Hyderabad, India
Jackie K Nguyen MD
Vitreoretinal Surgeon
Private Practice
Eyecare Medical Group
Portland, ME, USA
Quan Dong Nguyen MD MSc
Associate Professor of Ophthalmology
Diseases of the Retina and Vitreous, and
Uveitis
Wilmer Eye Institute
Johns Hopkins University School of
Medicine
Baltimore, MD, USA
Robert B Nussenblatt MD MPH
Chief
Laboratory of Immunology
National Eye Institute
National Institutes of Health
Bethesda, MD, USA
Masahito Ohji MD
Professor and Chairman
Department of Ophthalmology
Shiga University of Medical Science
Otsu, Shiga, Japan
Timothy W Olsen MD
F Phinizy Calhoun Sr Professor and
Chairman
Department of Ophthalmology
Emory University
Director, Emory Eye Center
Atlanta, GA, USA
Mrinali Patel MD
Postgraduate Student (PGY-1)
Memorial Sloan Kettering Cancer Center
NY, USA
Fernando M Penha MD PhD
Postdoctoral Associate,
Bascom Palmer Eye Institute, University
of Miami,
Miami, FL, USA
Postdoctoral Associate
Department of Ophthalmology
Federal University of São Paulo
São Paulo, Brazil
Hugo Quiroz-Mercado MD
Professor
Rocky Mountain Lions Eye Institute
University of Colorado Hospital
Aurora, CO, USA
Eduardo Büchele Rodrigues MD
Vision Institute, Department of
Ophthalmology
Federal University of São Paulo
São Paulo, Brazil
Mi In Roh MD
Opththalmology Research Fellow
Department of Ophthalmology
Harvard Medical School
Massachusetts Eye and Ear Infirmary
Boston, MA, USA
Juliana V Rossi MD
Retina and Vitreous Vision Institute
Department of Ophthalmology
Federal University of São Paulo
São Paulo, Brazil
Theodor Charles Sauer BS
Duke Medical School
Duke University
Durham, NC, USA
Osamu Sawada MD
Assistant Professor
Department of Ophthalmology
Shiga University of Medical Science
Otsu, Shiga, Japan
Andrew P Schachat MD
Professor of Ophthalmology, Lerner
College of Medicine
Vice Chairman
Cole Eye Institute
Cleveland Clinic Foundation
Cleveland, OH, USA
Ursula Schmidt-Erfurth MD
Professor and Chair
Department of Ophthalmology and
Optometry
Medical University of Vienna
Vienna, Austria
Hendrik P N Scholl MD MA
Consultant Ophthalmologist
Department of Ophthalmology
University of Bonn
Bonn, Germany
Stephen G Schwartz MD Mba
Associate Professor of Clinical
Ophthalmology
Medical Director, Bascom Palmer Eye
Institute at Naples
Naples, FL, USA
Syed Mahmood Shah Mbbs
Research Scientist
Wilmer Eye Institute
Johns Hopkins University School of
Medicine
Baltimore, MD, USA
Chirag Pradip Shah MD MPH
Vitreoretinal Surgery Fellow
Wills Eye Institute
Retina Service
Philadelphia, PA, USA
Carol L Shields MD
Professor of Ophthalmology
Ocular Oncology Service
Wills Eye Hospital
Philadelphia, PA, USA
xiv
Jerry A Shields MD
Professor of Ophthalmology
Thomas Jefferson University
Director, Oncology Services
Wills Eye Hospital
Philadelphia, PA, USA
Ravi J Singh MD
Department of Ophthalmology
Penn State College of Medicine
Hershey, PA, USA
Sobha Sivaprasad DM MS DNB FRCS
Consultant Ophthalmologist and Senior
Lecturer
Laser and Retinal Research Unit
Kings College Hospital
London, UK
Ricardo Luiz Smith MD PhD
Professor of Anatomy
Department of Morphology and Genetics
Federal University of São Paulo
São Paulo, Brazil
Ji Hun Song MD
Assistant Professor
Department of Ophthalmology
Ajou University School of Medicine
Suwon, South Korea
Gisèle Soubrane MD PhD
Professor and Chair of Ophthalmology Université de Paris Val de Marne Créteil, France
Boris V Stanzel MD
Resident in Ophthalmology
University Eye Hospital
Bonn, Germany
Einar Stefánsson MD PhD
Professor and Chairman
Department of Ophthalmology
Landspitali University Hospital
Reykjavik, Iceland
Glenn L Stoller MD
Private Practice
Ophthalmic Consultants of Long Island
Lynbrook, NY, USA
J Timothy Stout MD PhD MBA
Vice President, Oregon Health and
Science University
Professor of Genetics, Retina and
Vitreous Diseases
Casey Eye Institute
Portland, OR, USA
R C Andrew Symons MB BS PhD
FRANZCO
Assistant Professor of
Ophthalmology
Department of Ophthalmology
University of Kansas
Prairie Village, KS, USA
John T Thompson MD
Assistant Professor
Wilmer Eye Institute
Johns Hopkins University
Baltimore, MD, USA
Michael T Trese MD
Clinical Professor of Biomedical
Sciences, Oakland University, Rochester
Chief Pediatric and Adult Vitreoretinal
Surgery, Wm. Beaumont Hospital
Royal Oak, MI, USA
Harvey Siy Uy MD DPBO
Director for Research and Chief, Uveitis Service, Asian Eye Institute
Clinical Associate Professor of Ophthalmology
Jose Rizal Ophthalmology Center University of the Philippines Philippine General Hospital Makati City, Philippines
Monika Voigt MD PhD
Department of Ophthalmology of Créteil
University Paris XII
Créteil, France
Shawn Wilker MD
Assistant Professor of Ophthalmology
Case Western Reserve University
School of Medicine
Cleveland, OH, USA
George A Williams MD
Chair, Department of Ophthalmology
Clinical Professor
Beaumont School of Medicine
Oakland University
Beaumont Eye Institute
Royal Oak, MI, USA
Steven Yeh MD
Vitreoretinal Fellow
Casey Eye Institute
Portland, OR, USA
Ellen Yu-Keh MD
Asian Eye Institute
Makati City, Philippines
Donald J Zack MD PhD
Guerrieri Professor of Genetic
Engineering and Molecular
Ophthalmology
Johns Hopkins Medical School
Baltimore, MD, USA
David G. Zeballos MD
Retina and Vitreous Service
Clinica Oftalmológica Centro Caracas
Caracas, Venezuela
contributors of List
xv
